Navigation Links
MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results
Date:5/12/2008

MOUNTAIN VIEW, Calif., May 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the first quarter ended March 31, 2008.

The net loss for the first quarter ended March 31, 2008 was $14.3 million compared with $6.7 million during the same period in 2007. As of March 31, 2008, MAP Pharmaceuticals had cash, cash equivalents and short-term investments of $81.1 million.

First Quarter Financial Results

Research and development expenses for the first quarter ended March 31, 2008 were $11.8 million compared to $4.5 million for the same period in 2007. The increase in research and development expenses for the first quarter of 2008 was primarily related to increases in clinical trial expenses, personnel expenses to support Phase 3 clinical programs related to MAP Pharmaceuticals' two lead product candidates, and the attainment of a milestone related to the UDB program.

Sales, general and administrative expenses for the first quarter ended March 31, 2008 were $3.1 million compared to $1.7 million for the same period in 2007. The increase in sales, general and administrative expenses for the first quarter of 2008 was primarily related to increases in personnel expenses, share-based compensation and professional services.

MAP Pharmaceuticals had cash, cash equivalents and short-term investments as of March 31, 2008 of $81.1 million, compared to $95.0 million as of December 31, 2007. In addition, for the first quarter ended March 31, 2008, non-cash share-based compensation and depreciation was approximately $1.1 million.

"We are pleased with the progress we have made during the first quarter," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "For our Unit Dose Budesonide program for pediatric asthma, we initiated our first Phase 3 clinical trial and reported positive results from a Phase 2 pharmacokinetic trial comparing UDB to the currently marketed conventional nebulized budesonide. For our MAP0004 migraine program, we received a special protocol assessment (SPA) from the FDA, conducted investigator meetings and initiated clinical sites. We are working on manufacturing and qualification of clinical supplies with our external commercial manufacturing partners and upon completion of this work we expect to initiate this Phase 3 trial. Finally, we reported positive results from yet a third clinical program in a Phase 2a trial for MAP0005, a combination steroid and beta agonist product candidate."

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to our MAP0004 migraine program. Actual results may differ materially from current expectations based on risks and uncertainties affecting MAP Pharmaceuticals' business, including, without limitation, risks and uncertainties relating to the manufacture and qualification of clinical supply materials, our reliance on third-party manufacturers and the commencement, enrollment and conduct of clinical trials. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Annual Report on Form 10-K, filed with the SEC on March 20, 2008, and available at http://edgar.sec.gov.

MAP PHARMACEUTICALS, INC.

(a development stage enterprise)

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

March 31, December 31,

2008 2007

Assets

Current assets:

Cash, cash equivalents and short-term

investments $81,071 $94,990

Other current assets 859 1,079

Total current assets 81,930 96,069

Property and equipment, net 4,543 4,183

Restricted cash 321 321

Other assets 98 122

Total assets $86,892 $100,695

Liabilities and stockholders' equity

Current liabilities:

Accounts payable and accrued expenses $9,303 $8,912

Current portion of long-term debt 4,138 3,820

Total current liabilities 13,441 12,732

Long-term debt, less current portion 5,277 6,357

Total liabilities 18,718 19,089

Total stockholders' equity 68,174 81,606

Total liabilities and stockholders' equity $86,892 $100,695

MAP PHARMACEUTICALS, INC.

(a development stage enterprise)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share amounts)

(Unaudited)

Three Months Ended

March 31,

2008 2007

Operating expenses:

Research and development $11,815 $4,517

Sales, general and administrative 3,140 1,749

Total operating expenses 14,955 6,266

Loss from operations (14,955) (6,266)

Other income (expense), net 655 (393)

Net loss (14,300) (6,659)

Cumulative stock dividend

attributable to preferred

stockholders - (1,384)

Net loss attributable to common

stockholders $(14,300) $(8,043)

Net loss per share attributable to

common stockholders, basic and diluted $(0.71) $(10.77)

Weighted-average common shares used in

computing net loss per share

attributable to common stockholders,

basic and diluted 20,209,739 746,815


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Washington, DC (PRWEB) , ... ... ... the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to ... settings. The partnership will recruit top students from U.S. universities who will ...
(Date:2/12/2016)... Boca Raton, FL (PRWEB) , ... February 12, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – hosted over 250 members of South Florida’s philanthropic community at ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , ... , As Winston Churchill said, “Those who don’t learn from history are doomed to ... expect when they come knocking this year. But that takes time. , Take a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose Combination ... 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose combination ... garnering increased attention from all stakeholders in the development of new chemical entities. ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Each year, ... will be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical ... see new therapy products in action, learn more about their chosen field and network ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Va. , Feb. 12, 2016   National ... Hoey , RPh, MBA issued the following statement today ... released by the Centers for Medicare & ... raised by NCPA, beneficiary advocates and others: ... raised. We are still reviewing the full CMS analysis. ...
(Date:2/12/2016)...  This month,s issue of the Journal of ... in-depth look at various causes and consequences associated with rising health ... which has generated significant public outrage and calls for ... E. Happe , PharmD, MPH. --> JMCP ... --> In 2014 prescription drug spending in ...
(Date:2/12/2016)... PAULO , Feb. 12, 2016 ... commenced a cash tender offer (the "Tender Offer") ... million outstanding aggregate principal amount of its 6.500% ... and ISIN Nos. US44915JAA88/ USP5246AAF05) (the "Notes"). In ... soliciting (the "Consent Solicitation") consents (the "Consents") of ...
Breaking Medicine Technology: